US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.95 +1.12 (+3.04%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
From Beacon Biosignals
Via GlobeNewswire
News headline image
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences
Via Business Wire
News headline image
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
From Harmony Biosciences Holdings, Inc.
Via Business Wire
< Previous 1 2 3 Next >